Sfoglia per Autore
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
Identification and validation of PDGFRa as therapeutic target for PTCL-NOS.
2006 Piccaluga P.P.; Rossi M.; Iacobucci I.; Tazzari P.L.; Agostinelli C.; Zinzani P.L.; Bagnara G.P.; Martinelli G.; Dalla Favera R.; Baccarani M.; Pileri S.A.
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia
2006 S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Rondoni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani
Monitoring minimal residual disease and controlling drug resistance in chronicmyeloid leukaemia patients in treatment with imatinib as a guide to clinicalmanagement.
2006 Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
2006 IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia
2006 Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
2006 Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
2006 MARTINELLI G; IACOBUCCI I; ROSTI G; PANE F; AMABILE M; CASTAGNETTI F; CILLONI D; SOVERINI S; TESTONI N; SPECCHIA G; MERANTE S; ZACCARIA A; FRASSONI F; SAGLIO G; BACCARANI M.
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
2007 Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M.
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables
2007 Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A.
Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter?
2007 Soverini S.; Baccarani M.; Iacobucci I.; Martinelli G.
MK-0457: a light at the end of the tunnel?
2007 Martinelli G.; Soverini S.; Iacobucci I.; Baccarani M.
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
2007 Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients
2007 Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
2007 Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G.
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
2007 Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G.
Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio
2007 Iacobucci I; Galletti L; Amabile M; Soverini S; Baccarani M; Martinelli G.
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
2007 Soverini S; Iacobucci I; Baccarani M; Martinelli G.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. | Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; O...ttaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G | 2005-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
Identification and validation of PDGFRa as therapeutic target for PTCL-NOS. | Piccaluga P.P.; Rossi M.; Iacobucci I.; Tazzari P.L.; Agostinelli C.; Zinzani P.L.; Bagnara G.P.;... Martinelli G.; Dalla Favera R.; Baccarani M.; Pileri S.A. | 2006-01-01 | - | s.n | 4.02 Riassunto (Abstract) | - |
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia | S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Ron...doni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Monitoring minimal residual disease and controlling drug resistance in chronicmyeloid leukaemia patients in treatment with imatinib as a guide to clinicalmanagement. | Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M. | 2006-01-01 | HEMATOLOGICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. | IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFU...SCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia | Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruz...zese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cill...oni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients | MARTINELLI G; IACOBUCCI I; ROSTI G; PANE F; AMABILE M; CASTAGNETTI F; CILLONI D; SOVERINI S; TEST...ONI N; SPECCHIA G; MERANTE S; ZACCARIA A; FRASSONI F; SAGLIO G; BACCARANI M. | 2006-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance | Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M. | 2007-01-01 | BIOLOGICS | - | 1.01 Articolo in rivista | Martinelli_Biologics2007.pdf |
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables | Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A. | 2007-01-01 | - | Informa healthcare - Taylor & Francis publishers | 2.01 Capitolo / saggio in libro | - |
Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter? | Soverini S.; Baccarani M.; Iacobucci I.; Martinelli G. | 2007-01-01 | CLINICAL LEUKEMIA | - | 1.01 Articolo in rivista | - |
MK-0457: a light at the end of the tunnel? | Martinelli G.; Soverini S.; Iacobucci I.; Baccarani M. | 2007-01-01 | BLOOD | - | 1.04 Replica / breve intervento (e simili) | - |
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase | Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Par...ty on CML. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients | Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C;... Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B. | 2007-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain | Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga... PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. | Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Tes...toni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio | Iacobucci I; Galletti L; Amabile M; Soverini S; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. | Soverini S; Iacobucci I; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile